This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

22 Biopharma Stocks With Breakout Potential in 2012

Zalicus (ZLCS)
Drug/indication: Synavive AR in rheumatoid arthritis (phase II trial)
Top-line results expected in third quarter 2012
The "SYNERGY" trial evaluates the efficacy of Synavive AR, a combination pill comprised of the cardiovascular drug dipyridamole and a very low dose of the steroid prednisone, in patients with rheumatoid arthritis. Synavive is being compared with placebo and against the individual components. The study's primary endpoint is reduction in c-reactive protein (measured by DAS28 scale); key secondary endpoints are reductions in signs and symptoms of rheumatoid arthritis, measured by ACR20, ACR50 and ACR70 scales.

Ziopharm (ZIOP)
Drug/indication: Palifosfamide in sarcoma (phase III trial)
Top-line results expected in the second half of 2012
"PICASSO III" compares palifosfamide plus doxorubicin to doxorubicin alone in patients with front-line metastatic soft-tissue sarcoma. The study's primary endpoint is improvement in progression-free survival (for accelerated approval) and overall survival (for full approval). Sources: TheStreet research; BioMedTracker, a provider of independent research on biotechnology and pharmaceutical developments; and company and analyst reports.

>>To see these stocks in action, visit the 22 Biopharma Stocks With Breakout Potential in 2012 portfolio on Stockpickr.

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to

>To submit a news tip, send an email to:

Follow TheStreet on Twitter and become a fan on Facebook.
Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.
5 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ELN $0.00 0.00%
ACAD $18.47 4.00%
ARQL $1.62 -1.80%
BIIB $249.99 -0.31%
GERN $2.63 0.57%


Chart of I:DJI
DOW 16,014.38 -12.67 -0.08%
S&P 500 1,853.42 -0.02 -0.00%
NASDAQ 4,273.90 -9.8530 -0.23%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs